Zoetis price target raised to $200 from $190 at Argus

Argus raised the firm’s price target on Zoetis to $200 from $190 and keeps a Buy rating on the shares. The firm believes that the animal health industry has “solid long-term growth potential” and that Zoetis, as the largest pure-play animal health and vaccine company and the market leader in revenue, will “be able to optimize its leadership position,” the analyst tells investors.